0001104659-23-027680.txt : 20230302 0001104659-23-027680.hdr.sgml : 20230302 20230302080529 ACCESSION NUMBER: 0001104659-23-027680 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230228 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230302 DATE AS OF CHANGE: 20230302 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AVENUE THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001644963 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 474113275 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38114 FILM NUMBER: 23696480 BUSINESS ADDRESS: STREET 1: 1111 KANE CONCOURSE STREET 2: SUITE 301 CITY: BAY HARBOR ISLANDS STATE: FL ZIP: 33154 BUSINESS PHONE: 781-652-4500 MAIL ADDRESS: STREET 1: 1111 KANE CONCOURSE STREET 2: SUITE 301 CITY: BAY HARBOR ISLANDS STATE: FL ZIP: 33154 8-K 1 tm238198d1_8k.htm FORM 8-K
0001644963 false 0001644963 2023-02-28 2023-02-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

  

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): February 28, 2023

 

Avenue Therapeutics, Inc.

(Exact Name of Registrant as Specified in Charter)

 

Delaware
(State or Other Jurisdiction
of Incorporation)

001-38114
(Commission File Number)

 

47-4113275
(IRS Employer Identification No.)

 

 

1111 Kane Concourse, Suite 301

Bay Harbor Islands, Florida 33154

(Address of Principal Executive Offices)

 

(781) 652-4500

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act.
   
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
   
¨ Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
   
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

 

Securities registered pursuant to Section 12(b) of the Exchange Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which
registered
Common Stock ATXI Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 1.01. Entry into a Material Definitive Agreement.

 

On February 28, 2023, Avenue Therapeutics, Inc. (the “Company”) entered into a license agreement with AnnJi Pharmaceutical Co. Ltd., a Taiwanese company (“AnnJi”), whereby the Company obtained an exclusive license (the “License Agreement”) from AnnJi to intellectual property rights pertaining to the molecule known as JM17, which activates Nrf1 and Nrf2, enhances androgen receptor degradation and underlies AJ201, a clinical product candidate currently in a Phase 1b/2a clinical trial in the U.S. for the treatment of spinal and bulbar muscular atrophy (“SBMA”), also known as Kennedy’s Disease. Under the License Agreement, in exchange for exclusive (as described below) rights to the intellectual property underlying the AJ201 product candidate, the Company will pay an initial cash license fee of $3.0 million, of which $2.0 million is payable within 60 days and $1 million payable within 180 days after the effective date of the License Agreement. The Company is also obligated to issue shares of its common stock under the Subscription Agreement (described below) and make the following additional payments over the course of the License Agreement:

 

  · reimbursement payments of up to $10.8 million in connection with the product’s Phase 1b/2a clinical trial;
  · payments aggregating up to $14.5 million in connection with certain development milestones pertaining to the first indication in the U.S.;
  · payments aggregating up to approximately $27.5 million in connection with certain drug development milestones pertaining to additional indications and development ex-U.S.;
  · payments aggregating up to approximately $165 million upon the achievement of certain net sales milestones ranging from $75 million to $750 million in annual net sales; and
  · royalty payments based on a percentage of net sales, with such percentages ranging from the mid-single digits (on annual net sales at or below $50 million) to the low double digits (on annual net sales equal to or greater than $300 million), which are subject to potential diminution in certain circumstances.

 

In connection with the signing of the License Agreement, the Company will issue 831,618 shares of its common stock, par value $0.0001 per share (“Common Stock”), to AnnJi (the “First Tranche Shares”), and then will issue an additional 276,652 shares of Common Stock upon enrollment of the eighth patient in the ongoing Phase 1b/2a SBMA clinical trial (the “Second Tranche Shares” and, together with the First Tranche Shares, the “Consideration Shares”). The license provided under the License Agreement is exclusive as to all oral forms of AJ201 for use in all indications (other than androgenetic alopecia and Alzheimer’s disease) in the United States, Canada, the European Union, the United Kingdom and Israel. The License Agreement also contains customary representations and warranties and provisions related to confidentiality, diligence, indemnification and intellectual property protection. The Company will initially be obligated to obtain both clinical and commercial supply of AJ201 exclusively through AnnJi. This description of the License Agreement does not purport to be complete and is qualified in its entirety by the terms and conditions of the License Agreement to be filed with a subsequent periodic report of the Company.

 

The Company and AnnJi entered into a subscription agreement, dated as of February 28, 2023 (the “Subscription Agreement”) that provides for the issuance of First Tranche Shares, which contains customary representations and warranties of the Company and AnnJi, respectively, and is subject to customary closing conditions. The Company and AnnJi will enter into a subsequent subscription agreement, in substantially the same form as the Subscription Agreement, with respect to the issuance of the Second Tranche Shares. This description of the Subscription Agreement does not purport to be complete and is qualified in its entirety by the terms and conditions of the form of Subscription Agreement to be filed with a subsequent periodic filing of the Company.

 

Also in connection with execution of the License Agreement, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with AnnJi. Pursuant to the Registration Rights Agreement, the Company will be required to file, on or prior to August 28, 2023, a registration statement (the “Resale Registration Statement”) with the U.S. Securities and Exchange Commission (the “SEC”) to register the resale of the Consideration Shares. This description of the Registration Rights Agreement does not purport to be complete and is qualified in its entirety by the terms and conditions of the form of Registration Rights Agreement to be filed with a subsequent periodic report of the Company.

  

 

 

 

Item 3.02. Unregistered Sales of Equity Securities.

 

The information contained above in Item 1.01 is hereby incorporated by reference into this Item 3.02. Based in part upon the representations of AnnJi in the Subscription Agreement, the offering and sale of the Consideration Shares is exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506 of Regulation D promulgated under the Securities Act. The sales of the Consideration Shares by the Company have not been registered under the Securities Act or any state securities laws, and, accordingly, the Consideration Shares may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from the registration requirements. The sale of such securities does not involve a public offering and was made without general solicitation or general advertising. In the Subscription Agreement, AnnJi represented that it is an accredited investor, as such term is defined in Rule 501(a) of Regulation D under the Securities Act, and that it is acquiring the Consideration Shares for investment purposes only and not with a view to any resale, distribution or other disposition of the Consideration Shares in violation of the United States federal securities laws.

 

Item 8.01. Other Events.

 

On March 2, 2023, the Company issued a press release announcing the entry into the License Agreement and the transactions appurtenant thereto. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

The following exhibits are furnished herewith:

 

Exhibit
Number		   Description
99.1   Press release dated March 2, 2023
104   Cover Page Interactive Data File (embedded within Inline XBRL document)

  

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  AVENUE THERAPEUTICS, INC.
  (Registrant)  
Date: March 2, 2023    
  By: /s/ David Jin
    David Jin
    Interim Principal Financial Officer and Chief Operating Officer
     

  

 

 

 

 EX-99.1 2 tm238198d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

 

 

Avenue Therapeutics Enters into a Transformational License Agreement with AnnJi Pharmaceutical to Develop and Commercialize AJ201, a First-in-Class Clinical Asset for the Treatment of Spinal and Bulbar Muscular Atrophy

 

AJ201 is being evaluated in a Phase 1b/2a clinical trial in the U.S. for the rare X-linked genetic neurodegenerative disease also known as Kennedy’s Disease which currently has no FDA approved therapy

 

Miami, FL – March 2, 2023 – Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases, today announced that it has entered into an exclusive license agreement with AnnJi Pharmaceutical Co., Ltd. (“AnnJi”), a Taiwanese clinical-stage drug company, for AJ201, a first-in-class clinical asset currently in a Phase 1b/2a study in the U.S. for the treatment of spinal and bulbar muscular atrophy (“SBMA”), also known as Kennedy's Disease.

 

“The license for AJ201 brings a cutting-edge asset into Avenue’s pipeline that is the lead molecule in the clinic to treat Kennedy’s Disease, a debilitating rare neuromuscular disorder. With AJ201 leading the way, we are confident in the potential of our diversified portfolio of three assets to deliver value for investors in the near term and patients in the longer term,” said Alexandra MacLean, M.D., Chief Executive Officer of Avenue.

 

SBMA is a rare, inherited, X-linked genetic neuromuscular disease primarily affecting men. The condition is caused by a polyglutamine expansion in the androgen receptor (“AR”) which leads to production of an abnormal AR protein that forms aggregates responsible for muscle atrophy focused in the spinal-bulbar region of the body. The weakening of the bulbar muscles affects chewing, speech and swallowing, with patients prone to choking or inhaling foods or liquids, resulting in airway infection. SBMA also affects muscles in the limbs, leading to difficulty walking and injury caused by falling. Although there is a range of cited prevalence rates in the literature, a recent study used genetic analysis to estimate disease prevalence of 1:6,887 malesi. Currently, there is no effective treatment for SBMA.

 

AJ201 was designed to modify SBMA through multiple mechanisms including degradation of the abnormal AR protein and by stimulating Nrf1 and Nrf2, which are involved in protecting cells from oxidative stress which can lead to cell death. AJ201 completed a Phase 1 clinical trial in 2021, which demonstrated the safety of the molecule. It is currently being studied in a Phase 1b/2a multicenter, randomized, double-blind clinical trial in six clinical sites across the U.S., and screening of patients with SBMA has begun. This study aims to evaluate the safety and clinical response of AJ201 in patients suffering from SBMA. AJ201 has been granted Orphan Drug Designation (“ODD”) by the U.S. Food and Drug Administration for the indications of SBMA, Huntington’s Disease and Spinocerebellar Ataxia.

 

 

 

i M. Zanovello et al., Unexpected frequency of the pathogenic ARCAG repeat 2 expansion in the general population. Brain, in press (2023).

 

 

 

 

Exhibit 99.1

 

Under the terms of the license agreement, AnnJi will receive upfront payments of $3 million and is entitled to receive future development, regulatory and commercialization milestone payments, as well as royalties on net sales of the licensed product. Avenue will also issue 831,618 shares of its common stock to AnnJi in connection with the initial closing of the license transaction and up to an additional 276,652 shares upon achievement of a clinical milestone, aggregating in total to not more than 19.99% of the Company’s current total number of outstanding shares of common stock. The agreement includes the U.S., Canada, European Union, Great Britain and Israel as exclusively licensed territories.

 

Lindsay A. Rosenwald, M.D., Chairman of the Board of Avenue, stated, “We are excited to progress the clinical development of AJ201 to treat SBMA and further expand Avenue as a leading neurological company.”

 

About Avenue Therapeutics

 

Avenue Therapeutics, Inc. (Nasdaq: ATXI) is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic and rare diseases. It is currently developing three assets including AJ201, a first-in-class asset for spinal and bulbar muscular atrophy, BAER-101, an oral small molecule selective GABA-A α2/3 receptor positive allosteric modulator for CNS diseases, and IV Tramadol, which is in Phase 3 clinical development for the management of moderate-to-moderately-severe pain in adults in a medically supervised healthcare setting. Avenue is headquartered in Miami, FL and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). For more information, visit www.avenuetx.com.  

 

About AnnJi Pharmaceutical

 

Founded in 2014, AnnJi Pharmaceutical Co., Ltd. (“AnnJi”) is an R&D based, clinical-stage new drug company dedicated to the development of first-in-class small molecules focusing on indications with highly unmet needs in the therapeutic areas of neurology, dermatology, and inflammatory disorders, including rare diseases such as idiopathic pulmonary fibrosis and Kennedy’s disease, or SBMA (Spinal and bulbar muscular atrophy).

 

AnnJi’s mission is to develop innovative therapeutics to improve the quality of life of patients with neglected diseases. AnnJi’s goals are to translate and develop unique and highly differentiated drug therapies and to engage global collaborators and business partners in late-stage product development and commercialization.

 

 

 

 

Exhibit 99.1

 

Forward-Looking Statements

 

This press release contains predictive or “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of current or historical fact contained in this press release, including statements that express our intentions, plans, objectives, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “will,” “should,” “would” and similar expressions are intended to identify forward-looking statements. These statements are based on current expectations, estimates and projections made by management about our business, our industry and other conditions affecting our financial condition, results of operations or business prospects. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in, or implied by, the forward-looking statements due to numerous risks and uncertainties. Factors that could cause such outcomes and results to differ include, but are not limited to, risks and uncertainties arising from: expectations for increases or decreases in expenses; expectations for the clinical and pre-clinical development, manufacturing, regulatory approval, and commercialization of our pharmaceutical product candidate or any other products we may acquire or in-license; our use of clinical research centers and other contractors; expectations for incurring capital expenditures to expand our research and development and manufacturing capabilities; expectations for generating revenue or becoming profitable on a sustained basis; expectations or ability to enter into marketing and other partnership agreements; expectations or ability to enter into product acquisition and in-licensing transactions; expectations or ability to build our own commercial infrastructure to manufacture, market and sell our product candidate; acceptance of our products by doctors, patients or payors; our ability to compete against other companies and research institutions; our ability to secure adequate protection for our intellectual property; our ability to attract and retain key personnel; availability of reimbursement for our products; estimates of the sufficiency of our existing cash and cash equivalents and investments to finance our operating requirements, including expectations regarding the value and liquidity of our investments; the volatility of our stock price; expected losses expectations for future capital requirements; and those risks discussed in our filings which we make with the SEC. Any forward-looking statements speak only as of the date on which they are made, and we undertake no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances that may arise after the date of this press release, except as required by applicable law. Investors should evaluate any statements made by us in light of these important factors.

 

Contact:

Jaclyn Jaffe

Avenue Therapeutics, Inc.

(781) 652-4500

ir@avenuetx.com

 

 

 

 EX-101.SCH 3 atxi-20230228.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 atxi-20230228_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 atxi-20230228_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm238198d1_ex99-1img01.jpg GRAPHIC begin 644 tm238198d1_ex99-1img01.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Cover
Feb. 28, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 28, 2023
Entity File Number 001-38114
Entity Registrant Name Avenue Therapeutics, Inc.
Entity Central Index Key 0001644963
Entity Tax Identification Number 47-4113275
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 1111 Kane Concourse
Entity Address, Address Line Two Suite 301
Entity Address, City or Town Bay Harbor Islands
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33154
City Area Code 781
Local Phone Number 652-4500
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol ATXI
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 tm238198d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001644963 2023-02-28 2023-02-28 iso4217:USD shares iso4217:USD shares 0001644963 false 8-K 2023-02-28 Avenue Therapeutics, Inc. DE 001-38114 47-4113275 1111 Kane Concourse Suite 301 Bay Harbor Islands FL 33154 781 652-4500 false false false false Common Stock ATXI NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://avenuetx.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm238198d1_8k.htm atxi-20230228.xsd atxi-20230228_lab.xml atxi-20230228_pre.xml tm238198d1_ex99-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm238198d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2021q4": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "tm238198d1_8k.htm" ] }, "labelLink": { "local": [ "atxi-20230228_lab.xml" ] }, "presentationLink": { "local": [ "atxi-20230228_pre.xml" ] }, "schema": { "local": [ "atxi-20230228.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "atxi", "nsuri": "http://avenuetx.com/20230228", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm238198d1_8k.htm", "contextRef": "From2023-02-28to2023-02-28", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://avenuetx.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm238198d1_8k.htm", "contextRef": "From2023-02-28to2023-02-28", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001104659-23-027680-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-027680-xbrl.zip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end